Putaminal y‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease
Background Motor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain. Objectives The aim of this study is to determine whether putaminal y‐aminobutyric acid (GABA)...
Saved in:
Published in | Movement disorders Vol. 36; no. 9; pp. 2187 - 2192 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.09.2021
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Motor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain.
Objectives
The aim of this study is to determine whether putaminal y‐aminobutyric acid (GABA) levels are associated with dopaminergic motor response.
Methods
We assessed putaminal GABA levels in 19 PD patients and 13 healthy controls (HCs) utilizing ultra‐high field proton magnetic resonance spectroscopy. Motor performance was evaluated using the Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Part III, in the ON and OFF states. Statistical analysis comprised group comparisons, correlation analysis, and multiple linear regression.
Results
In PD, GABA levels were significantly higher compared to HCs (1.50 ± 0.26 mM vs. 1.26 ± 0.31 mM, P = 0.022). Furthermore, GABA levels were independent predictors of absolute and relative dopaminergic treatment response.
Conclusions
Our findings indicate that elevated putaminal GABA levels are associated with worse dopaminergic response in PD, emphasizing the essential role of nondopaminergic neurotransmitters in motor response. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society |
---|---|
Bibliography: | All authors have no financial disclosures to declare and no conflicts of interests with regard to this manuscript. Else Kröner‐Fresenius‐Stiftung (grant number 2019_EKES.02); Koeln Fortune Program, Faculty of Medicine, University of Cologne (grant number 453/2018); Clinician Scientist Program (CCSP), Faculty of Medicine, University of Cologne, funded by the German Research Foundation (DFG, FI 773/15‐1); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project‐ID 431549029, SFB 1451; Shota Rustaveli National Science Foundation, Tbilisi, Georgia (grant number JFZ_18_02). Relevant conflicts of interest/financial disclosures Funding agencies ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0885-3185 1531-8257 |
DOI: | 10.1002/mds.28674 |